Evidence map›Paper›PMID 33173221›Full record

ArticleScientific reports2020

Fate and functional roles of Prominin 1

Raymond Wu, Stephanie Pan, Yibu Chen, Yasuhiro Nakano, Meng Li, Steven Balog, Hidekazu Tsukamoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Raymond WuSouthern California Research Center for ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Stephanie PanSouthern California Research Center for ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yibu ChenUSC Libraries Bioinformatics Services, University of Southern California, Los Angeles, CA, USA.
Yasuhiro NakanoCenter for Matrix Biology and Medicine, Graduate School of Medicine, Tokai University, Isehara, Japan.
Meng LiUSC Libraries Bioinformatics Services, University of Southern California, Los Angeles, CA, USA.
Steven BalogSouthern California Research Center for ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Hidekazu TsukamotoSouthern California Research Center for ALPD and Cirrhosis and Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. htsukamo@usc.edu.
University of Southern California · USTokyo Medical and Dental University · JPVA Greater Los Angeles Healthcare System · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Ming Li · 1985 to 2026
$181.4M
The Southernearch Center for ALPD and CirrhosisP50AA011999 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ANNA S. GUKOVSKAYA · 1999 to 2026
$45.8M
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI OOKHTENS, MURAD · 1995 to 2020
$21.8M
NON-PARENCHYMAL LIVER CELL CORER24AA012885 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TSUKAMOTO, HIDEKAZU · 2001 to 2025
$8.1M
Epigenetic Regulation of Alcoholic Liver FibrosisU01AA018663 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KISSELEVA, TATIANA, MANN, DEREK · 2010 to 2019
$3.7M
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitorsU01AA027681 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI EL-KHOUEIRY, ANTHONY BOUTROS, KARIN, MICHAEL · 2018 to 2022
$3.6M
Molecular Mechanisms of Stellate Cell Activation in Liver FibrosisI01BX001991 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI HIDEKAZU TSUKAMOTO · 2014 to 2026
–
BLRD VA I01 BX001991BLRD VA IK6 BX004205NCI NIH HHS P30 CA014089NIAAA NIH HHS P50 AA011999NIAAA NIH HHS P50AA011999NIAAA NIH HHS R24 AA012885NIAAA NIH HHS U01 AA018663NIAAA NIH HHS U01 AA027681NIDDK NIH HHS P30 DK048522NIH HHS U01AA027681
6 · The paper itself

Abstract

Prominin 1 (PROM1) is one of a few clinically relevant progenitor markers in human alcoholic hepatitis (AH) and hepatocellular carcinoma (HCC), and mouse liver tumor initiating stem cell-like cells (TICs). However, the origin, fate and functions of PROM1

Indexed as

AC133 AntigenAnimalsCarcinoma, HepatocellularCells, CulturedDiscoidin Domain Receptor 1Hepatitis, AlcoholicHepatocytesHumansLiverLiver NeoplasmsMiceAC133 AntigenDDR1 protein, humanDdr1 protein, mouseDiscoidin Domain Receptor 1PROM1 protein, humanProm1 protein, mouse

Identifiers

PMID33173221
PMCPMC7656457
OpenAlexW3102389154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.